Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Clinical trial NCT06785584 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06785584
Sponsor: Fujian Medical University Union Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

ALK-positive Advanced NSCLC ALK-positive Non-small Cell Lung Cancer (NSCLC)MPR Neoadjuvant Therapy

Start date: 2025-02-01
Primary completion: 2025-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.